Skip to main navigation Skip to search Skip to main content

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

  • Michael J. Robertson
  • , Brad S. Kahl
  • , Julie M. Vose
  • , Sven De Vos
  • , Mary Laughlin
  • , Patrick J. Flynn
  • , Kendrith Rowland
  • , Jose C. Cruz
  • , Stuart L. Goldberg
  • , Luna Musib
  • , Christelle Darstein
  • , Nathan Enas
  • , Jeffery L. Kutok
  • , Jon C. Aster
  • , Donna Neuberg
  • , Kerry J. Savage
  • , Ann LaCasce
  • , Donald Thornton
  • , Christopher A. Slapak
  • , Margaret A. Shipp

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science